RMC-8839
RMC-8839 is an orally active selective RAS (ON) G13C inhibitor with a Ki value of 28.3 nM. RMC-8839 disrupts the interaction between KRASG13C and RAF1 (RBD). RMC-8839 inhibits RAS-MAPK pathway signaling by reducing DUSP6 mRNA levels and pERK levels. RMC-8839 induces cytotoxicity, apoptosis (apoptosis) and antiproliferative effects in KRASG13C-mutated cells. RMC-8839 induces tumor stasis or regression in mice. RMC-8839 can be used in research related to non-small cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 2953305-55-8
- Formula: C54H72F3N9O8
- Molecular Weight:1032.20
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
KRAS G13C 28.3 nM (Ki) |
In Vitro
RMC-8839 (50 nM; 6-72 h) potently and selectively reduces the viability of MLE-12 cells expressing KRASG13C and inhibits the MAPK signaling pathway, with an IC50 of 135 nM, while exhibiting extremely low activity against other KRAS mutants[1].
RMC-8839 selectively reduces the viability of BEAS-2B cells expressing KRASG13C, with an IC25 of 7.5 nM[1].
RMC-8839 (5-625 nM; 0-4 h) disrupts the KRASG13C-RAF1 (RBD) complex in U-2 OS cells, exhibits 55-fold selectivity for mutant KRASG13C over wild-type KRAS, and has an EC50 of approximately 2 nM against KRASG13C[2].
RMC-8839 (10 pM-10 μM; 4 h) inhibits pERK in KRASG13C-mutant NCI-H1734 cells with an EC50 of approximately 3 nM, and exhibits 22-fold selectivity over wild-type RAS NCI-H1975 cells[2].
RMC-8839 (10 pM-10 μM; 5 days) inhibits the viability of NCI-H1734 cells harboring the KRASG13C mutation, with an EC50 of approximately 0.3 nM[2].
RMC-8839 (100 nM; 24-168 h) selectively inhibits the MAPK signaling pathway and reduces the viability of H1734, MOR, HCC4087, and H1355 cell lines with IC50 values of 20.3, 43.5, 477, and 1202 nM, respectively, while inducing apoptosis in sensitive KRASG13C cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MLE-12 cells expressing FLAG-tagged KRAS variants
-
Concentration:50 nM
-
Incubation Time:6 h
-
Result:Completely cross-linked FLAG-tagged KRASG13C and strongly inhibited ERK 1/2 phosphorylation in KRASG13C MLE-12 cells.
Caused only partial cross-linking and modest ERK 1/2 inhibition in KRASG12C cells.
Exerted no effect on other KRAS variants.
In Vivo
RMC-8839 (10-100 mg/kg; p.o.; once daily; for 28 consecutive days) exhibits dose-dependent tumor growth inhibition in the NCI-H1734 xenograft mice model[2].
RMC-8839 (100 mg/kg; p.o.; once daily; for 28 consecutive days) induces tumor regression in the ST2822B KRASG13C-mutant non-small cell lung cancer PDX nude mouse model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD SCID (female, 6-8 weeks old, subcutaneous xenograft model)[1]
-
Dosage:100 mg/kg (monotherapy); 100 mg/kg + 5 mg/kg Docetaxel (HY-B0011) (combination)
-
Administration:p.o.; daily; 28 days (monotherapy); p.o.; daily; 28 days + i.v.; single dose; day 0 (combination)
-
Result:Induced tumor growth inhibition compared to vehicle control.
Drove significant tumor regression, with all nine tumors exhibiting greater than 80% tumor volume reduction when combined with Docetaxel.
Achieved statistically significant combination index scores of 0.077 (Highest Single Agent model) and 0.2333 (Bliss Independence model), where CI < 1 indicates synergy.
Was well-tolerated as measured by body weight assessment.
-
Animal Model:NOD SCID (female, 6-8 weeks old)[2]
-
Dosage:10 mg/kg; 25 mg/kg; 100 mg/kg (daily dosing for 28 days); 10 mg/kg; 50 mg/kg; 100 mg/kg (single dose)
-
Administration:p.o.; daily; 28 days; p.o. (single dose)
-
Result:Achieved >90% tumor target engagement within 3 hours and maintained above 75% for 24 hours with a single 100 mg/kg oral dose.
Reached >95% tumor RAS-MAPK pathway suppression (via human DUSP6 mRNA levels) and maintained above 80% for 24 hours with a single 100 mg/kg oral dose.
Slowed tumor growth with 10 mg/kg daily dosing for 28 days.
Further reduced tumor growth with 25 mg/kg daily dosing for 28 days.
Achieved tumor stasis with 100 mg/kg daily dosing for 28 days.
Showed sustained suppression of RAS pathway signaling in tumors collected 8 hours after the final dose of 25 mg/kg and 100 mg/kg.
Maintained stable body weight with all doses, indicating good tolerability.
-
Animal Model:Crl:NU(NCr)-Foxn1nu (female, 6-12 weeks old)[2]
-
Dosage:100 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Induced tumor regressions after 28 days of daily 100 mg/kg dosing.
Chemical Information
-
CAS No. 2953305-55-8
-
Molecular Weight 1032.20
-
Formula C54H72F3N9O8
-
SMILES
C[C@H](OC)C1=[C@@]([C@@]2=C(CC(C)(C)COC([C@H]3NN(C([C@H](CN4CC5=CCC4)NC([C@H](C(C)C)N(C)C(N6CCC7(OCN(C(C=C)=O)[C@H]7C)CC6)=O)=O)=O)CCC3)=O)C8=C(C=CC5=C8)N2CC(F)(F)F)C=CC=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
[1]. McDaid WJ, et al. Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer. Cancer Discov. 2026 Jun 22. [Content Brief]
[2]. Seamon KJ, et al. Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant Cancers. Cancer discovery. 2026 Jun 22. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)